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ABSTRACT 
TITLE – A Clinical Study On Cystoid Macular Edema 
AIM  :   To study the epidemiology of cystoid macular edema and 
analyse the effectiveness of intravitreal triamcinolone acetonide in 
treatment of refractory cystoid macular edema. 
MATERIALS AND METHODS : This prospective, non 
randomized  clinical study was conducted at Regional Institute of 
Ophthalmology, Chennai in Vitreo retina clinic. 40 eyes of 32 patients 
were analysed and followed up for a period of 6 months. 
OBSERVATIONS AND RESULTS : The mean age of presentation 
was 58.33 ± 9.5 years with a male : female ratio of 1.9:1. Diabetes 
was found to be the leading cause. The reduction in mean macular 
thickness was significant in all three groups with diabetic macular 
edema(423.13±196.55µm) and pseudophakic macular edema 
(450.55±126.38µm) having a good reduction compared to retinal vein 
occlusion group. All patients had a significant 2 Snellen line visual 
improvement. The correlation between macular thickness and visual 
acuity was weak positive in post treatment. Increase in intraocular 
pressure was noted in 22.5% cases responding to medical therapy 
with 1 case needed a surgical intervention. 
CONCLUSION : The  fall  in  Mean  macular  thickness  after  IVTA  
was statistically significant in all three groups analysed.The visual 
acuity improvement also was statistically significant (p<0.0001) but 
correlation with macular thickness was weak positive. Intravitreal 
triamcinolone acetonide is a promising therapy in  refractory cystoid 
macular edema in terms of safety and effectiveness. 
KEYWORDS : Refractory cystoid macular edema, mean macular 
thickness, visual acuity, intraocular pressure. 
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ABBREVIATIONS 
 
CME  – Cystoid macular edema 
FFA  – Fundus fluorescein angiography 
OCT  – Optical coherence tomography 
AC – Anterior chamber 
NSAIDs – Non steroidal anti inflammatory drugs 
Nd-Yag – Neodymium Yttrium Argon Garnet  
ILM  – Internal limiting membrane 
CNVM  –  Choroidal neovascular membrane 
CSR  – Central serous retinopathy 
RPE  – Retinal pigment epithelium 
NPDR  – Non proliferative diabetic retinopathy 
FAZ  – Foveal avascular zone 
CRVO  – Central retinal vein occlusion 
BRVO  – Branch retinal vein occlusion 
ERM  – Epiretinal membrane 
DM  – Diabetes mellitus 
TNF  – Tumour necrosis factor 
CSME  – Clinically significant macular edema 
ACIOL  – Anterior chamber intraocular lens 
PCIOL  – Posterior chamber intraocular lens 
OPL  – Outer plexiform layer 
DME  – Diabetic macular edema 
NFL  – Nerve fibre layer 
PAM  – Potential acuity meter 
ERG  – Electroretinogram 
FERG  – Foveal  electroretinogram 
ETDRS – Early treatment Diabetic Retinopathy study 
FDA  – Food and drug administration 
RP  – Retinitis pigmentosa 
PPV  – Parsplana vitrectomy 
ARMD  – Age related macular degeneration 
VEGF  – Vascular endothelial growth factor 
PKP  – Penetrating keratoplasty 
IVTA  – Intravitreal triamcinolone acetonide 
SCORE – Standard vs Corticosteroid for retinal vein occlusion study 
RD  – Retinal detachment 
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INTRODUCTION 
 Retinal edema is a common condition occuring due to circulatory 
disturbances and in inflammatory conditions. Macular edema is broadly 
defined as an abnormal thickening of macula with accumulation of excess 
fluid in the extracellular spaces of retina. 
 Cystoid macular edema is an accumulation of fluid in cyst like 
spaces within the macula in the outer plexiform layer. It is a common 
pathological response to a wide variety of ocular insults. It is thought that 
prostaglandin secretion and vascular endothelial damage causes fluid 
accumulation in the relatively loose intercellular adhesions of outer 
plexiform layer which permits the formation of cystoid spaces. 
 Macular edema due to various causes forms the leading cause of 
central vision loss in the world and therefore gained enormous 
importance. 
 Aphakic and Pseudophakic cystoid macular edema, commonly 
referred to as Irvine-Gass syndrome, has been recognised as a distinct 
entity since 1953 after its description by Irvine and Gass and by Norton in 
1966. It is one of the most frequent and troublesome problem following 
cataract surgery. With recent improvements in sutures, instruments, 
techniques and antibiotic therapy, loss of central vision secondary to 
changes in macula following uneventful cataract extraction has received 
recognition as a major complication of cataract surgery. 
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REVIEW OF LITERATURE 
 1953 – Irvine described a syndrome of spontaneous rupture of the 
hyaloid face following uneventful cataract extraction. There was 
irritability of eye and decreased visual acuity secondary to vitreous 
opacities and macular degeneration. 
 1954 – Schepens noted attachment of the vitreous at the vitreous 
base, disc and macula. 
 1955 - Schepens reported macular clouding followed by a macular 
break which in turn lead to retinal detachment, due to vitreous shrinkage 
and traction. 
 1965 – Tolentino and Schepens presented a series of cases of 
edema of posterior retina after cataract extraction. In most of them they 
were able to demonstrate vitreous strands attaching to the macula and 
occasionally to optic disc. They attributed the change to vitreo-retinal 
traction. 
 1966 – Gass and Norton further described the condition and gave it 
the title “Cystoid Macular Edema”. They illustrated the characteristic 
clinical and FFA picture and described in detail the biomicroscopic 
appearance of the lesion. 
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 1966 – Iliff gave the vitreous traction theory. 
 1968 – Gass and Norton did partial open sky vitrectomy under 
microscopic control using cellulose sponge and scissors. 
 1970 – Mechanized vitrector was used for limbal and parsplana 
vitrectomy. 
 1977 – Miyake first used NSAIDs like topical indomethacin in the 
treatment of CME following cataract surgery. 
 1983 – Katzen, Fleischman, Trokel used the Nd-Yag laser for 
vitreolysis. 
 1991 – Shahidi, Ogura determined that retinal thickness as 
measured by biomicroscopy and stereophotography correlates well with 
visual acuity. 
 1995 – Arend and Remby used fluorescein angiography generated 
with scanning laser ophthalmoscope for early recognition of cystoid 
formation in CME. 
 1995 – Hee and Puliafito used the optical coherence tomography 
for objectively monitoring retinal thickness in patients with CME. 
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ANATOMY OF MACULA 
 Macula is the optical, functional and organic focal point of the eye 
concerned with precise visual functions of acuity, form sense, colour, 
differentiation and stereopsis. 
 There is no anatomical landmark to define this zone on clinical 
examination or on morphological basis. It is approximately a circle with 
radius of 2.75mm centred at fovea (5.5mm in diameter). The yellow 
colour of macula is due to xanthophyll pigments in ganglion cells. The 
side walls of macula slope gently towards the fovea centralis. 
 Fovea centralis is the depression in the inner retinal surface in the 
centre of macula and is 1.5mm in diameter and 0.25mm in thickness. 
 Foveola is 0.35mm in diameter and 0.13 mm in thickness 
occupying centre of fovea. It is situated 4mm temporal and 0.8mm 
inferior to optic nerve head. Rod cone ratio is about 1:2 in this region. 
 A small depression in the centre of foveola is called umbo. 
 Parafoveal zone is an area measuring 0.5mm surrounding the 
fovea. Rod cone ratio is about 1:1. 
 Perifoveal zone is 1.5mm wide zone surrounding the parafoveal 
area. 
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BLOOD SUPPLY OF MACULA 
     Macular region is supplied by small twigs from superior and inferior 
branches of central retinal artery. In 20% of individuals, cilioretinal 
artery, a branch from the ciliary system of vessels supply the macula. 
Capillaries are arranged as three layered in the macula and they are 
reduced to single layer in the perifoveal area and in centre is the capillary 
free zone of 400-600µm in diameter. 
BLOOD RETINAL BARRIER 
 Outer Blood Retinal Barrier 
 This is formed by the tight junctions (Zonulae occludens and 
Zonulae adherens) of retinal pigment epithelial cells. 
 Inner Blood Retinal Barrier 
 The endothelial cells of retinal capillaries are bound together about 
the lumen by intercellular junctions of zonulae occludens type and forms 
the inner blood retinal barrier. 
  
ANATOMY OF FOVEA 
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Dotted circle represents the macular region 
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MICROANATOMY OF MACULA 
 Retina at macula is made of three types of cells and their synapses 
arranged from without inwards in the following layers 
¾ Retinal pigment epithelium 
¾ Layer of rod and cones 
¾ External limiting membrane 
¾ Outer nuclear layer 
¾ Outer plexiform layer 
¾ Inner nuclear layer 
¾ Inner plexiform layer 
¾ Ganglion cell layer (multilayered in comparison to rest of retina) 
¾ Nerve fibre layer  
¾ Internal limiting membrane. 
 In Cystoid Macular Edema there is accumulation of fluid between 
outer plexiform and inner nuclear layer. 
FOVEA CENTRALIS 
 This region is predominated by cones and are arranged obliquely 
forming the Henle’s layer.  
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FOVEOLA 
 This region of retina contains cones and their nuclei covered by 
thin internal limiting membrane. Remaining retinal layers (Inner nuclear 
layer, Inner plexiform layer, ganglion cell layer and nerve fibre layer) are 
absent in foveola. 
HENLE’S FIBRE LAYER 
 The outer plexiform layer is made up of arborisation of axons of 
rods and cones with bipolar cell dendrites. It includes Muller’s fibres and 
Horizontal cell processes. This layer has a reticular structure but as 
macula is approached it takes up a fibrous structure called Henle’s layer. 
The fibres run vertically at first and then obliquely near macula and 
finally parallel to surface which is thickest at macula and absent at 
foveola. There is progressive disappearance of rods.(1) 
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ANATOMICAL PECULIARITIES OF MACULA CAUSING AN 
EXAGGERATED RESPONSE TO PATHOLOGICAL PROCESSES 
 The peculiar susceptibility of the macula to a number of different 
pathological processes, both local and general is called the “exaggerated 
response of macula” (2). Anatomical causes for this are: 
 Vascular supply – The arcade arrangement of capillaries which 
arise as terminal parts of an end artery system together with the central 
avascular zone make the foveolar region a watershed. Local impairment 
of metabolism whether from disturbances of perfusion and accumulation 
of metabolites or from the effects of capillary damage leads to 
extracellular fluid collection at a quicker rate than they can be absorbed. 
Also the capillaries at fovea are longer and vascular complexes are 
thinner than elsewhere hence they are more susceptible to noxious 
substances. 
1. Tissue architecture – The processes of Muller’s cells run 
horizontally in outer plexiform layer hence retina loses its compact 
nature and this laxity enables large quantities of extracellular fluid 
to be accumulated in the macular region leading to characteristic 
cystoid edema. 
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2. Cellular constituents – The ganglion cells have high metabolic 
activity and their dysfunction leads to rapid accumulation of tissue 
metabolites. Most of these have a vasodilator effect and this along 
with the underlying hypoxia leads to edema. 
3. Internal limiting membrane – The vitreous is an excellent diffusion 
medium and the ILM provides little additional interference to the 
progress of toxic substances diffusing across it. Inflammatory 
toxins arising from the iris, peripheral choroid and pars plana may 
traverse the vitreous and because of the thinness and adherence of 
ILM in foveal region, they may preferentially disturb the function 
of cells which are highly concentrated around foveal rim and also 
affect the macular capillary permeability. 
4. Choroid and RPE – The macular choroid and RPE are also the 
preferential sites for degenerative changes which may be 
hereditary, toxic or arteriosclerotic in nature. There is a 
predisposition for choroidal vascular disease with decompensation 
and hemorrhage in the central area which is thought to be because, 
RPE in fovea is very active metabolically and this hyperactivity 
along with special hemodynamic effects of narrow choroidal 
capillaries in this region may lead to increased susceptibility.  
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EVALUATION OF MACULAR DISEASES 
SLIT LAMP BIOMICROSCOPY 
           It utilises high power convex lenses to obtain wide field of view of 
the fundus which is vertically inverted and laterally reversed. It provides 
high magnification with stereopsis to detect macular disease. 
AMSLER GRID TEST 
             It evaluates central 200 of visual field on fixation and hence 
useful in screening and monitoring the macular disease. There are 7 
charts. Chart 1 is most commonly used. This chart consists of white grid 
on black background with 400 small, 5mm squares, each square subtends 
an angle of 10 when viewed at 33cm. Each eye is checked individually, 
with the chart held at 33cm with prior correction for presbyopia. Patients 
are asked to maintain fixation on the central dot and comment on four 
corners, any missing areas on chart and wavy lines. 
FUNDUS FLUORESCEIN ANGIOGRAPHY 
             Fluorescence is the property of certain molecules to absorb light 
of shorter wavelength and emit light of longer wavelength. This is the 
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principle used in fundus fluorescein angiography and is valuable in 
evaluation of macular diseases. 
             Sodium fluorescein is a water soluble orange dye, 3ml of 25% 
fluorescein is injected intravenously through antecubital vein, 85% is 
bound to plasma proteins and remains intravascular. Passage of dye 
through retinal and choroidal circulations is studied through photographic 
surveillance. 
¾ Phases in FFA – Choroidal phase, Arterial Phase, Arteriovenous 
phase, Venous phase, Recirculation phase. 
¾ Causes of Hyperfluorescence – Autofluorescence, 
Pseudofluorescence, Window defect, Pooling, Leakage, Staining. 
¾ Causes of Hypofluorescence – Masking of Retinal fluorescence, 
Masking of Choroidal fluorescence, Filling defects. 
OPTICAL COHERENCE TOMOGRAPHY 
 OCT is a non invasive, non contact imaging system that provides 
high resolution cross sectional images of retina, optic nerve head and the 
vitreous. 
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 Principle – OCT is based on imaging of reflected light (near 
infrared light), analogous to B scan. The difference is that OCT uses low 
coherence interferometry and measures optical rather than acoustic or 
radiowave reflectivity. 
 OCT is used to differentiate lamellar and full thickness macular 
hole, to determine treatment options in CNVM, monitoring the course of 
CSR, retinal thickness map, to identify type of macular edema and to 
monitor its course and so on. 
¾ High Reflectivity – Nerve fibre layer, RPE, Choriocapillaries, 
Pigment accumulation, Naevus, Neovascularisation, RPE 
hypertrophy. 
¾ Medium reflectivity – Plexiform layer. 
 Low Reflectivity – Nuclear layer, Photoreceptors, Retinal edema, 
Cystoid edema, Cavity, Cyst, Pigment epithelial detachment, Serous 
retinal detachment.  
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The macular edema patterns seen on OCT are as follow: 
1. Sponge like Retina 
 It is mostly confined to outer retinal layers ue to backscattering 
from intra retinal fluid. 
2. Cystoid macular edema 
 Cystoid spaces confined to outer retina mostly. In long standing 
cases they fuse to form large cyst. 
3.  Serous retinal detachment 
 Hypo reflective space under fovea. It may disappear following 
laser. 
4.  Tractional retinal detachment 
 Foveo vitreal traction causes detachment of fovea. Its an indication 
fors Pars Plana Vitrectomy to release traction. Laser will worsen macular 
edema in these cases. 
5. Taut Posterior Hyaloid Membrane 
 Cystoid spaces confined to outer retina mostly. In long standing 
cases they fuse to form large cyst. 
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CYSTOID MACULAR EDEMA 
 The extracellular space of the retina normally constitutes a small 
proportion of its total volume. Active transport of electrolytes and larger 
molecules from retina across the retinal pigment epithelium to the blood 
maintains this space. Disruption of either inner or outer retinal barrier 
leads to leakage of plasma proteins and water which leads to expansion of 
extracellular space of retina. This is often accompanied by accumulation 
of fluid in the outer plexiform and inner nuclear layer of retina. Retinal 
edema localized to macula is called macular edema leading to diffuse 
thickening of posterior pole. Accumulation of fluid in cystic spaces leads 
to cystoid macular edema. 
CAUSES OF CYSTOID MACULAR EDEMA 
 Cause of cystoid degeneration of macula as described by Duke 
Elder are (3) 
 1. Senile degeneration. 
2. Vascular disorders - Arteriosclerosis, CRVO, CRAO, 
Retinal periphlebitis, Hypertensive retinopathy, Diabetic 
retinopathy. 
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 3. Inflammatory conditions - chorioretinitis, iridocyclitis. 
 4. Degenerative conditions of macula - Retinal dystrophies, 
Retinitis pigmentosa. 
 5 Trauma - usually in contusions or associated with retention 
of foreign body, radiation injury like eclipse blindness. 
 6. Glaucoma. 
 7. Hereditary macular dystrophy.  
  Other conditions as mentioned by Stephen J. Ryan are(4) 
 8. Drugs - Epinephrine maculopathy, Nicotinic acid 
maculopathy. 
 9. Post surgical - After any type of cataract surgery, vitrectomy, 
glaucoma procedures, penetrating keratoplasty. 
 10. Tumours - choroidal hemangioma, choroidal melanoma. 
 11. Retinal detachment. 
 12. Tractional maculopathies – Epiretinal membrane, 
Vitreomacular traction syndrome. 
 13. Optic nerve head abnormalities – Optic disc pit, coloboma, 
diabetic papillopathy. 
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CME IN RETINAL VASCULAR DISEASES 
x  Diabetic Cystoid Macular Edema  
 It is the most common cause of visual impairment in patients with 
NPDR. This is best detected by slitlamp biomicroscopy with +90 D, +78 
D and Fundus contact lens. 
 Incidence of macular edema increases with type of diabetes, 
duration of diabetes, age of onset, use of insulin, uncontrolled diabetes, 
associated risk factors like hypertension, hyperlipidemia, anemia, 
nephropathy. It is more common in type 2 diabetes. 
Pathophysiology  
 Hyperglycemia is the main inciting factor which causes disruption 
of retinal vasculature that breaks blood retinal barrier and leakage from 
microaneurysms and capillaries. Focal retinal hypoxia causes an increase 
in hydrostatic pressure that in turn increases luminal hydrostatic pressure. 
This causes dilatation of capillaries with disruption of tight junctions 
between endothelial cells and favouring fluid egress and macular edema. 
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Clinical features   
1. Thickening of macula 
2. Blurring of underlying choroidal vascular pattern 
3. Loss of foveolar reflex 
4. Cystoid spaces 
5. Lipid exudation from leaking microaneurysms forming circinate 
maculopathy. 
Classification of types of edema  
1. Focal Edema – Areas of focal leakage from microaneurysms 
forming partial or complete ring of hard exudates delineated from 
adjacent healthy retina. 
2.  Diffuse Edema – Areas of leakage from microaneurysms and 
dilated capillary segments throughout posterior retina causes 
diffuse edema. It differs from focal edema by 
a) Diffuse edema is not associated with hard exudates. 
b) It develops cystoid spaces more commonly and better seen in 
late phases of FFA and on OCT as hyper reflective spaces 
with hyper reflective septa. 
 c) It is bilaterally symmetrical. 
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 d) It may disappear spontaneously even without laser only to 
reappear spontaneously. 
 e) Systemic features may be associated with exacerbations and 
amelioration of diabetic macular edema. 
3. Ischemic Edema – It is associated with enlargement of FAZ, 
irregularties of FAZ, capillary budding into FAZ, widening of 
intercapillary spaces and capillary dropout in perifoveal area. 
Clinically Significant Macular Edema (CSME) 
1. Thickening of retina within 500µm from centre of macula. 
2. Hard exudates with retinal thickening seen within 500µm from 
centre of macula. 
3. A zone of retinal thickening about 1 disc diameter in size, a portion 
of which is seen within 1 disc diameter from centre of macula. 
FFA  
 Focal edema shows areas of leakage mainly from microaneurysms 
in late phases. Diffuse edema shows dilated capillary network with areas 
of capillary nonperfusion with extravasations of dye in late phases. If 
leakage occurs in flower petal pattern, cystoid macular edema is present. 
 DIABETIC  MACULAR EDEMA 
 
 
 
 
        Figure -1 Colour Fundus       Figure - 2 FFA early Phase 
 
 
 
 
 
 
      Figure - 3 FFA Mid Phase       Figure - 4  FFA Late Phase 
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x  Retinal Vein Occlusion Induced Cystoid Macular Edema 
 In CRVO and BRVO, macular edema tends to be chronic, difficult 
to treat and visually disabling. Visual loss is exacerbated by macular 
haemorrhages, macular ischemia, secondary RPE changes like ERM. 
Pathophysiology 
x Elevation in intravascular pressure in the retinal veins distal to 
occlusion site causes increase in transmural hydrostatic pressure in 
retinal capillaries leading to greater transudation of fluid into 
extracellular spaces. 
x Disruption of microscopic intraretinal connections due to cytokines 
mediated by hypoxic retina  greatly facilitates extravasation of 
fluids as well as large protein molecule(5). 
x Development of fluid blood levels in central cystoid spaces is 
characteristic of obstructive retinopathy. 
  
CRVO WITH CYSTOID MACULAR EDEMA 
 
 
FFA PICTURE 
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POST OPERATIVE CYSTOID MACULAR EDEMA 
 It is the most common cause of vision loss after cataract surgery.  
A higher incidence is seen when surgery is complicated by vitreous loss, 
vitreous adhesions to cataract wound, iris damage or retained lens 
material. 
 The risk of developing CME is higher in patients with associated 
factors like DM and Uveitis (vasoactive stimuli). 
Pathophysiology 
x  Vitreous Traction Theory 
 Constant constriction and dilatation of pupil created pulling effect 
on the anterior vitreous strands which was transmitted to the vitreous base 
and to macula by presumed vitreous connections between posterior 
hyaloid and surface of macula- VITREOUS TUG SYNDROME. 
x  Inflammation Theory 
 CME following cataract extraction (Irvine-Gass ) syndrome can be 
seen in approximately 20% of uncomplicated cases.(6) 
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 Eyes with CME nearly always demonstrate signs of intraocular 
inflammation and responds to steroid therapy. Aqueous humour contains 
biochemically active principles called Aqueous Biotoxic Complex factors 
which manifest biotoxic effects when it leaves its natural reservoir. These 
diffuse posteriorly through collapsed liquefied vitreous gel. The liquefied 
vitreous anterior to retina assumes chemical and osmotic properties that 
are not normally present resulting in outpouring of fluid from perimacular 
capillaries. 
 Since eye does not contain enzyme 15-Pg dehydrogenase to 
deactivate prostaglandins, their removal is dependent on active transport 
pump called Bito’s(23) pump located in the ciliary epithelium which is 
inoperable for atleast 3weeks post trauma. 
 Inflammatory state persists for longer periods when vitreous is 
adherent to cataract wound causing pupillary distortion. 
x  Anoxic Theory 
 An association between CME and systemic conditions like 
hypertension, diabetes mellitus, arteriosclerotic disease is seen in which 
anoxia could be a predisposing factor. 
22 
 
CME In ACIOL 
     Chronic uveal irritation may either stimulate production of intra 
ocular inflammatory substances or may retard the absorption or removal 
of these substances by non pigmented epithelium of ciliary body. An 
ACIOL can press against anterior surface of iris or apply constant 
pressure over ciliary body which could trigger anterior uveal 
inflammation. 
CME In PCIOL 
1. No pupillary distortion and intact posterior capsule 
 a. Sulcus fixated IOL – chronic irritation of uveal tissue 
because of direct contact can lead to CME 
 b. In the bag IOL – Incidence of CME is low. 
2. Pupillary distortion – Distortion by pupillary capture or by 
synechiae between remnants of anterior capsule and posterior 
surface of iris can lead to persistent uveal irritation leading to 
CME. The degree of irritation is not as great as produced by pupil 
distorted by wick of vitreous adherent to corneoscleral wound. 
CME In Phacoemulsification 
 There could be a greater incidence during learning curve because 
of increased intraocular manoeuvring and greater risk of complications. 
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CME In Posterior Yag Capsulotomy 
1. Primary Surgical Posterior Capsulotomy 
 There is a higher incidence of CME because posterior capsule acts 
as a barrier to posterior diffusion of inflammatory mediators and to 
anterior movement of vitreous. 
2. Secondary Nd-Yag Capsulotomy 
x Broken capsule no longer acts as a barrier for posterior 
diffusion of inflammatory mediators. 
x Inadvertent rupture of anterior hyaloid face. 
x Post laser intraocular inflammation.  
CME IN UVEITIS 
Pathophysiology 
 Disruption of blood retinal barrier secondary to inflammatory 
mediators like Cytokines, Interferon-ܵ, Interleukin-2 and 10, TNF-Į. 
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THEORIES CONCERNING ORIGIN OF CYSTS OF CME 
x  Intracellular Theory 
 Yanoff et al. proposed that cysts develop from degenerating 
Muller’s cells. Initially these cells demonstrate edema which gradually 
increases until cytoplasm of cells begin to develop vacuoles. These 
edematous cells gradually expand until cell walls break and adjoining 
cells form larger cavities leading to cysts in CME. A breakdown in blood 
retinal barrier or anoxia is the prime cause for edema. 
x  Extracellular Theory 
 Gass, Anderson and Davis proposed that cysts arise from 
expansion of extracellular spaces of retina by serous exudation within the 
outer plexiform layer and inner nuclear layer. This involves leakage of 
serous exudates from perifoveal intraretinal capillaries and sometimes 
from disc capillaries. These exudates form small puddles in OPL of Henle 
which acts like a sponge because of peculiar nature of macula.  
 This theory is supported by highly reversible function of CME eye 
which argues against cellular death and disruption and, visible lack of 
occluded capillaries in macula which argues against presence of anoxia. 
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CLINICAL FEATURES OF CYSTOID MACULAR EDEMA 
SYMPTOMS 
 It is usually asymptomatic. If severe, defective vision, 
metamorphosia, scotomas can occur. 
SIGNS 
Fundus    
x Characteristic honey comb like lesion showing one or more cystoid 
spaces centrally with many small oval spaces around them.  
x Sometimes only loss of foveal reflex is seen. 
x Cystoid spaces are best seen with red free filter which makes inner 
walls visible. 
x Retina may be markedly thickened and lesion as large as 1.5-2 disc 
diameters. 
x Some cases are associated with disc edema. 
 Anterior segment- Usually shows signs of inflammation. The 
anterior hyaloid face is broken or intact and vitreous shows cells, vitreous 
opacities and posterior vitreous detachment.  
COLOUR FUNDUS PHOTOGRAPH OF CYSTOID 
MACULAR EDEMA 
 
 
DRAWING OF FUNDUS AND BIOMICROSCOPIC 
APPEARANCE OF CME 
 
 
 
 
 
 
(as originally drawn by Gass and Norton in 1966) 
26 
 
CLINICAL EVALUATION OF CYSTOID  
MACULAR  EDEMA 
1. VISUAL ACUITY 
 Best corrected visual acuity and with pin hole should be assessed. 
Loss of vision depends on the involvement of macula. Severity of vision 
loss correlates well with amount of macular edema. 
2. PERIMETRY  
 Field charting by perimetry may reveal scotoma corresponding to 
areas of involvement in fundus. 
3. COLOUR VISION 
 The most common defect is blue . In diabetes the sensitivity of blue 
cones is depressed. These are best detected by Farnsworth munsell 100 
hue test. 
4. DIRECT OPHTHALMOSCOPY 
 Monochromatic light is better for detecting subtle macular changes, 
hence red free light is used. But lack of stereoscopic view is a 
disadvantage. 
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5. SLIT LAMP BIOMICROSCOPY WITH 90D, 78D, HRUBY 
LENS, GOLDMANN THREE MIRROR CONTACT LENS 
 The  optical  section  of  convex  anterior  walls  of  cysts  can  be  seen  
overlying empty vesicles tightly packed together with their interfaces 
presenting a spidery pattern. 
 With slit beam, it is possible to see a network of interlacing fine 
refractile lines by retroillumination. 
 Advantages of using stereopsis and slit lamp optics. 
6. INDIRECT OPHTHALMOSCOPY 
 This provides an entire view of retina allows examiner to have an 
understanding of  the cause in various pathological features of retina.  
 It gives less magnification. 
7. RETINAL PHOTOGRAPHY 
 Photographs are taken with fundus camera and selected films and 
colour filters. Red free light is used for detecting subtle changes in ILM 
and NFL. 
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8. STEREOPHOTOGRAPHY 
 Two  photographs  are  taken  along  parallel  axes  on  either  side  of  
dilated pupil producing stereoscopic pair. The separation of images can 
be adjusted to reproduce the normal depth relationships and to allow 
depth measurements. 
9. MADDOX ROD TEST 
 The patient is asked to look at distant light through a Maddox rod. 
If the red line is continuous and unbroken, macular function is good. 
10. AMSLER GRID TEST 
 Central distortion of the grids or a relative central scotoma may be 
seen in CME. 
11. ENTOPTIC IMAGERY 
 The globe is steadily and firmly massaged through the closed lower 
lids,  with  bare  lighted  bulb  of  a  torch.  The  entire  vascular  tree  of  the  
retina is seen on an orange background. Any blanks or scotoma in the 
central area implies macular involvement. 
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12. POTENTIAL ACUITY METER 
 It is for differentiating between visual loss from anterior segment 
disease and macular disease. The PAM attaches easily to a standard slit 
lamp and projects a Snellen’s visual acuity chart into eye using a 1.5mm 
diameter pin hole aperture. The patient is tested at different points on the 
cornea in an attempt to project through the clearer areas in the lens. 
13. MACULAR PHOTOSTRESS TEST OR AFTER IMAGE 
SCOTOMETRY 
 The patient looks at a flash light held 2cm from the eye for 10 
seconds. The time it takes for visual recovery to one line less than the 
visual acuity determined prior to this test is measured. The normal 
recovery time is 55seconds. Longer recovery time, upto 90-180 seconds 
implies macular dysfunction even though the area may appear 
anatomically normal. The rapidity of recovery relates to the rate of visual 
purple regeneration and rapidity of vitamin A transport from RPE to 
photoreceptors. Difference between two eyes is also significant. 
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14. CLINICAL INTERFEROMETERS 
 In cases of opaque media, beams of coherent light from two point 
sources are directed through the clearest area of the lens into retina. 
Interference fringes on the retina are formed wherever the two beams 
overlap and by varying the width of the inter fringe pattern, the visual 
acuity can be determined. 
15. ELECTROPHYSIOLOGICAL ASSESSMENT 
 Foveal ERG is a test of the temporal responsiveness of the central 
100 of the retina and requires integrity of the outer retinal layers, 
especially Muller’s cells. FERG is usually abnormal in 35% of eyes with 
CME. Pattern ERG reflects the inner retinal layer function. It is usually 
abnormal  in  53%  of  eye  with  CME.  It  is  the  test  of  the  temporal  
responsiveness of central 100 of the retina. 
16. VISUAL EVOKED POTENTIAL 
 In macular disease with fluid accumulation, the VEP shows 
amplitude reduction depending on the decreased visual acuity with no 
change in latency. 
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IMAGING MODALITIES IN CYSTOID MACULAR EDEMA 
¾  FUNDUS FLUORESCEIN ANGIOGRAPHY 
 FFA is mandatory for following purposes: 
x Confirm and document macular changes 
x Deciding the management 
x Follow up. 
 It allows examination of structures in the macular region which are 
beyond the reach of direct ophthalmoscopy and also helps to study the 
hemodynamic changes that occur in the retina and localized abnormalities 
of flow and perfusion that are the background to many pathological 
disturbances.  
 In CME, within 1-2 minutes of injection, in the arteriovenous 
phase, early leakage of the dye in the parafoveal area is seen. In some 
instances, focal points of leakage with confluence of leaking areas will be 
noted. A characteristic flower petal appearance is evident in late 
arteriovenous phase in the parafoveal region.  Fovea itself appears dark 
and does not always show leakage. The late phase shows marked edema 
with persistent pooling of dye in cystoid spaces.  
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 The dark septae in the macular area which compartmentalize the 
pattern are because of the Muller’s fibres. The spaces appear to 
intercommunicate. Usually there is considerable leakage of dye into 
vitreous and aqueous anteriorly. In some patients with disc edema, there 
may be leakage of dye into optic nerve and peripapillary retina. 
¾  OPTICAL COHERENCE TOMOGRAPHY 
 This investigative modality can also be used for diagnosis and 
follow up. It has added advantage of being non-invasive.  
 In addition parameters like macular thickness can be quantified on 
subsequent visits.  
 Cystoid spaces confined to outer retina mostly. In long standing 
cases they fuse to form large cyst. 
  
 FFA  PICTURE SHOWING CHARACTERISTIC 
FLOWER PETAL LEAKAGE PATTERN 
 
 
 
 
  
OCT PICTURE SHOWING CYSTOID SPACES 
 
 
EPIRETINAL MEMBRANE 
    
 
OCT PICTURE SHOWING EPIRETINAL MEMBRANE 
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TREATMENT MODALITIES FOR MACULAR EDEMA 
1. LASER PHOTOCOAGULATION  
 Macular edema secondary to vascular causes like diabetic 
retinopathy and retinal vein occlusions respond well to focal and grid 
laser photocoagulation. Focal laser is used to close microaneurysms and 
grid laser stimulates RPE pump to clear the edema. 
 The Early Treatment for Diabetic Retinopathy Study (ETDRS) 
established guidelines for laser treatment in diabetic macular edema(7). 
Laser treatment is indicated for clinically significant macular edema as 
per definition stated before. Moderate visual loss was reduced to 50% in 
patients who received laser therapy in ETDRS.  
 Grid laser has proven benefit in patients with BRVO but not in 
CRVO. In Branch Vein Occlusion Study, 65% of grid laser treated eyes 
gained atleast 2 lines of vision, compared with 37% of untreated eyes(8). 
In Central Vein Occlusion Study, grid laser did not have any significant 
effect on vision, although there was a trend towards better vision in 
patients aged <60 years who underwent laser treatment. 
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2. MEDICAL MANAGEMENT 
¾  TOPICAL THERAPY  
 Several studies have documented the utility of topical NSAIDs for 
both the prevention and treatment of macular edema after cataract 
surgery(9). A double masked, randomized, placebo controlled trial to 
evaluate the effect of Ketorolac 0.5% ophthalmic solution on chronic 
pseudophakic and aphakic CME determined that this drug is beneficial 
for the primary outcome measure (Snellen’s acuity)(10). The efficacy of 
topical Flurbiprofen 0.03% and Indomethacin 1% in preventing 
pseudophakic CME was examined in a randomized, double masked study 
that revealed a reduced incidence of clinical and angiographic CME in 
the early postoperative period. Recently, two new topical NSAIDs, 
Bromfenac 0.09% and Nepafenac 0.1% have been FDA approved for 
cataract surgery inflammation and pain. There have been reports, 
particularly for Nepafenac, of their potential for preventing pseudophakic 
CME.(11) Nepafenac is a prodrug that is converted after corneal 
penetration to Amfenac, a potent NSAID. In one animal model, 
Nepafenac was shown to inhibit prostaglandin in the vitreous humour to a 
much greater extent than other traditional NSAIDs. Whether this efficacy 
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will translate into improved prevention or treatment of pseudophakic 
CME is currently under investigation. 
 Corticosteroids drops alone or in combination with NSAID drops, 
have been studied for the treatment of pseudophakic CME. Treatment 
with topical NSAIDs appears to be more effective than topical steroids 
alone. However, combination therapy with topical NSAIDs and 
Prednisolone acetate was superior to either one alone in treating CME. 
Consensus for topical NSAIDs  use has not been established formally, 
however,  the  standard  of  care  for  many cataract  surgeons  is  to  use  both  
NSAIDs and topical steroids for atleast 1 to 2 days preoperatively and for 
several weeks postoperatively. In higher risk patients, such as those with 
pre-existing ocular inflammation or diabetes, extended preoperative and 
postoperative use is typically employed. Patients must be monitored for 
side effects of both NSAIDs (corneal toxicity) and corticosteroid use 
(increased intraocular pressure). 
¾  SYSTEMIC THERAPY  
x Systemic NSAIDs have been examined as a treatment of uveitic 
CME.  A  recent  study  of  oral  Naproxen  or  Rofecoxib  revealed  
that these medications had no effect on CME. However, these 
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patients also had active, intraocular inflammation. NSAIDs may 
have  a  role  in  the  prevention  of  recurrence  of  CME  after  
inflammation is controlled, although this scenario is still under 
investigation(12).  The  potential  for  NSAIDs  to  cause  
gastrointestinal ulceration or liver toxicity must be addressed 
with patients before initiating this therapy.  
x Carbonic anhydrase inhibitors reduce macular edema that can 
occur in association with retinitis pigmentosa (RP). A 
randomized crossover study demonstrated that improvement in 
visual acuity in >80% of all RP patients who received 
Acetazolamide(13). The usual starting dose is 500mg/day. 
Sometimes these are also used to treat uveitis associated CME, 
although potential benefits have not been established. There is 
also a conflicting evidence for CAI use, as in one study group 
there was a significant improvement in visual acuity in treated 
group while another failed to show an improvement despite 
reduction in macular edema evident on FFA(14). The usefulness 
in pseudophakic CME is even less robust. 
x Systemic corticosteroids have a long history of use in treatment 
of uveitic CME. In severe cases, intravenous steroids are 
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recommended during induction therapy. Treatment is initiated 
with high dose of 1mg/kg body weight, followed by a slow 
taper over several weeks to months. Tapering the steroids too 
rapidly is associated with higher recurrence. The short term side 
effects of steroids are mood alterations, difficulty sleeping, 
increased appetite, potential for worsening of a diabetic state. 
There are a few reports of successful use of systemic steroids in 
the treatment of recalcitrant cases of pseudophakic CME. 
x Steroid sparing immunomodulators have also been useful in 
uveitic CME but its utility in macular edema is less clear. 
PERIOCULAR CORTICOSTEROIDS 
 Corticosteroids are used in treatment of macular edema as they 
influence by multiple pathways, the factors responsible for breakdown of 
blood retinal barrier and edema. They inhibit VEGF and other cytokines 
and growth factors that regulate endothelial tight junctions. They also 
reduce the synthesis of prostaglandins and leukotrienes, potent 
inflammatory mediators. Periocular steroids may be given as peribulbar 
or subtenon’s space with equivalent benefit. Both these methods give a 
more sustained treatment than topical steroid drops alone. Peribulbar 
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injections give a short term benefit in some cases of macular edema 
induced by Diabetes, BRVO, CRVO, Pseudophakia. Periocular injections 
are of particular benefit in cases of uveitis that are not responsive to 
topical therapy. They decrease both inflammation and retinal thickening 
produced by macular edema. 
¾  INTRAVITREAL STEROIDS 
 Corticosteroids by their anti inflammatory effect will contribute to 
reduction in edema. Increased diffusion by modulation of calcium 
channels also could account for efficacy of corticosteroids.(15) 
 In last few years, intravitreal triamcinolone (IVTA) has gained 
widespread use as a treatment in all forms of macular edema. IVTA 
reduces retinal thickening on OCT and improves vision in a substantial 
number of patients. Patients with cystoid component respond better. The 
duration of effect varies and macular edema recurrence and visual decline 
are observed 4 to 6 months after injection. Repeated therapy is often 
limited by side effects. Intraocular pressure elevation occurs in about one 
third of patients, which can (rarely) require glaucoma surgery. 
Acceleration of cataract formation, endophthalmitis are other 
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complications associated with the procedure which should be considered 
and discussed with the patient as a part of informed consent.  
 IVTA has also been used in macular edema associated with vein 
occlusion. A recently published 1 year study revealed a short term visual 
benefit in patients with CRVO associated macular edema who were 
treated for macular edema with IVTA, although their vision generally 
returned to pretreatment levels at 1 year despite repeated injections(16). It 
has also been observed that rate of intraocular pressure rise and need for 
glaucoma surgery appears to be higher in this subset of patients than in 
those with diabetic macular edema. The SCORE (Standard Care Vs 
Corticosteroid for Retinal Vein Occlusion) Study, a National Eye Institute 
– sponsored randomized clinical trial of intravitreal steroid for BRVO and 
CRVO associated Macular edema clearly mentions the benefit of IVTA 
as compared to standard therapy in CRVO. In cases of macular edema 
due to BRVO, IVTA and Grid laser shows a comparable response, 
however, IVTA can be used for macular edema not responding to grid 
laser therapy. 
 Finally IVTA has been used in uveitic CME. A retrospective 
review of 16 patients with chronic, refractory uveitic CME who received 
atleast 1 injection of IVTA had results that mirrored those seen when this 
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medication was used as a treatment for macular edema caused by other 
diseases(17).  At  a  mean  follow  up  of  34  weeks,  there  was  a  sustained  
improvement in visual acuity in 55% patients, although there was a 
relapse or persistence of CME in half of all patients receiving this 
treatment. One of the 20 eyes required glaucoma implant surgery for 
increased intraocular pressure. 
¾  INTRAVITREAL DRUG DELIVERY SYSTEMS 
 Recently multiple alternative steroid delivery devices has arrived 
for treatment of macular edema. There are currently four corticosteroid-
based intravitreal implants under development.  
 These include:  
x Dexamethasone biodegradable implant (Posurdex®) 
x Helical triamcinolone acetonide implant (I-vation™ ) 
x Fluocinolone acetonide implant (Retisert®) 
x Fluocinolone acetonide – based implant that is injectable 
(Medidur™) 
 OZURDEX is an intravitreal implant containing 0.7 mg (700 mcg) 
dexamethasone in the NOVADUR solid polymer drug delivery 
system.Iteffective in reducing macular edema for a period of 3 months.  
OZURDEX – INTRAVITREAL DEXAMETHASONE 
IMPLANT 
 
 
OZURDEX  APPLICATOR 
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INTRAVITREAL ANTI VEGF COMPOUNDS   
 Anti VEGF agents work to restore the normal permeability of the 
blood retinal barrier. Pegaptanib sodium, an anti VEGF pegylated 
aptamer,  has  been  studied  in  a  phase  II  randomized,  double  blind,  
controlled trial of DME in 172 subjects.(18) Patients received atleast 3 
injections  at  6  week  intervals  and  were  followed  for  36  weeks.  The  
patients assigned to pegaptanib were more likely to gain atleast 10 letters 
(34% vs 10%, p=0.003) were more likely to show a reduction in central 
macular thickness (42% vs 16%, p=0.02) and at follow up examinations 
were deemed less likely to need additional photocoagulation therapy 
(25% vs 48%, p=0.04).  
 Ranibizumab (LucentisTM), another intravitreal anti VEGF agent 
that has been FDA approved for treatment of wet age related macular 
degeneration, was studied in a small series of 10 patients with DME and 
found to significantly reduce foveal thickness and improve vision(19). 
Larger randomized trials are necessary to assess the significance of this 
preliminary finding.  
 Bevacizumab (AvastinTM) is a recombinant, humanized, 
monoclonal antibody directed against VEGF. Avastin has received FDA 
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approval as an intravenous drug for treatment of metastatic colon cancer. 
An intravitreal formulation was first used off label for the treatment of 
ARMD. In cases of diffuse DME that failed other treatments, intravitreal 
injection of Bevacizumab was associated with improved vision and 
decreased retinal thickness 12 weeks after the first injection(20). Most of 
the patients received >1 bevacizumab injection during follow up. A 
recent study of intravitreal bevacizumab treatment for macular edema in 
patients with CRVO revealed a significant decrease in mean central 
thickness (887 to 372µm, p< 0.001), and improved visual acuity (defined 
as halving the visual angle) in 14 of 16 eyes(21). Patients had received an 
average of 2.8 injections and were followed for a mean of 3 months. No 
adverse outcomes occurred. These encouraging short term results need to 
be validated in prospective studies. Bevacizumab has been tried in 
patients with macular edema secondary to uveitis. In one case series, in 
which  patients  were  followed  for  atleast  2  months   after  a  single  
intravitreal njection, about 70% of treated patients had a decrease in 
foveal thickness but only 40% of patients had improved visual acuity by   
>2 lines.(22) Thus  for  patients  with  difficult  to  control  macular  edema,  
bevacizumab may be a therapeutic option with reasonably good 
outcomes. 
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¾  Nd-Yag LASER VITREOLYSIS 
 Elevated vitreous strands are transacted using Nd-Yag laser. 
Bisecting vitreous membranes that are adherent to the anterior surface of 
iris may be difficult without producing small haemorrhages which diffuse 
into aqueous and make accurate focussing impossible. Therefore laser 
treatment is primarily used in those cases in which vitreous strands bridge 
the margin of pupil to undersurface of cataract wound without adhering to 
anterior surface of iris. 
¾  SURGICAL THERAPY 
S.NO SITUATIONS OPTIONS 
1. Intracameral lens within the 
pupil iris suspended 
Remove/exchange for 
flexible ACIOL or SFIOL 
2. ACIOL with / without 
distorted pupil with vitreous 
in AC 
Vitrectomy (for restoration 
of distorted pupil) with 
secondary IOL 
3. PCIOL with pupillary 
capture 
Free the capture 
4. PCIOL with moderate 
papillary distortion from 
vitreous strands 
Anterior vitrectomy for 
restoring pupil and consider 
leaving IOL 
5. PCIOL sulcus fixated with 
normal pupil 
Consider removing IOL with 
/ without 20IOL 
6. PCIOL in the bag with 
normal pupil 
Rule out other causes of 
CME and PPV if there is a 
evidence of traction on 
macula. 
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CME DUE TO OTHER CAUSES 
x  AGE RELATED MACULAR DEGENERATION 
 CME occurs if serous detachment present for 3-6 months or if 
subretinal neovascularisation has progressed to cover subfoveal area. 
 Causes are anoxia and RPE destruction. 
 Treatment by any therapy has a poor prognosis. 
x  CHOROIDAL TUMOURS 
 Malignant melanoma, capillary hemangioma, naevi can cause 
CME due to prevention of nutrients and oxygen from reaching the retina. 
 Treatment is to treat the cause. 
x  CHRONIC UVEITIS 
 CME is due to breakdown of blood retinal barrier.  
 Treatment is to treat uveitis. 
x  RETINITIS PIGMENTOSA 
 RPE and perifoveal capillaries are more permeable. Acetazolamide 
has a role in treating CME due to RP. 
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x CME DUE TO OTHER SURGERY LIKE RD SURGERY, 
PKP 
 There is a 40% incidence of CME in aphakic eyes undergoing RD 
surgery and 25% in phakic eyes. There is 40% incidence following PKP. 
SEQUELAE OF CME   
 Permanent macular degeneration may arise secondary to prolonged 
chronic CME. The cystoid spaces of the macula may coalesce together so 
that all retinal elements disappear except for the ILM. After the ILM also 
disintegrates, a lamellar hole is formed which may be one fourth to one 
third disc diameter in size. In the presence of lamellar hole, the visual 
acuity may continue to be good because of retention of some percipient 
elements.  
BIOMICROSCOPY OF LAMELLAR HOLE 
 It is sometimes difficult to differentiate from a large foveal cystoid 
space with the ILM intact. The degenerative macular hole has gradual 
sloping margins and irregular edges. The border later becomes well 
defined by 4 months to one year. 
  
  
 
PART - II 
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AIM OF THE STUDY 
 To study the epidemiology of cystoid macular edema and analyse 
the effectiveness of intravitreal triamcinolone acetonide in treatment of 
refractory cystoid macular edema. 
PRIMARY OBJECTIVES 
1. To study the epidemiology of  refractory cystoid macular edema. 
2. To study the effectiveness of intravitreal triamcinolone acetonide in 
treatment of refractory cystoid macular edema in terms of visual 
acuity and central macular thickness. 
SECONDARY OBJECTIVES 
1. To evaluate safety of intravitreal injection of triamcinolone 
acetonide. 
INCLUSION CRITERIA 
1.  Central macular thickness on OCT more than 300µm. 
2. Refractory diffuse diabetic macular edema not responding to grid 
laser photocoagulation. 
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3.  Refractory pseudophakic cystoid macular edema not responding to 
topical anti-inflammatory drugs and grid laser photocoagulation. 
4.  Cystoid macular edema due to vein occlusions that was refractory 
to grid laser photocoagulation. 
5. Patients who accepted treatment and had a follow up period of at 
least 12 weeks. 
EXCLUSION CRITERIA 
1. Patients with history or signs of uveitis. 
2. Patients with other pre-existing macular degenerations due to 
causes like ARMD, RP, etc. 
3.  Patients  with  aphakic  CME  and  pseudophakic  CME  with  
complications like pupillary capture, subluxated IOL, vitreous 
incarceration at wound site needing surgical correction. 
4. Patients with CME following other surgical procedures like RD 
surgery, Combined surgery, Penetrating keratoplasty, etc. 
5. Patients with history of glaucoma or ocular hypertension. 
48 
 
 6. Patients on systemic corticosteroid therapy. 
 7. Patients with Vitreomacular traction or taut posterior hyaloid 
on OCT. 
REFRACTORY  MACULAR EDEMA  
¾ In this study, all diabetic patients received atleast 2 sessions of 
laser photocoagulation according to ETDRS guidelines, and last 
laser treatment was atleast 4 months before IVTA treatment. All 
eyes considered for IVTA had residual retinal thickening with 
visual acuity less than 6/18 on Snellen’s chart and macular 
thickness more than 300µm by OCT.  
¾ All eyes of vein occlusion induced macular edema received laser 
photocoagulation and which were refractory to treatment with 
central macular thickness more than 300µm.  
¾ All eyes that presented with pseudophakic cystoid macular edema 
that were refractory to topical anti-inflammatory drugs and grid 
laser photocoagulation and central macular thickness more than 
300µm. 
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MATERIALS AND METHODS 
 This prospective study was carried out at Regional institute of 
ophthalmology, Chennai in Vitreo-retina clinic from November 2011 to 
November 2013. Patients who were referred to Vitreo-retina clinic with a 
provisional diagnosis of diabetic macular edema, pseudophakic CME, 
BRVO, CRVO were screened and selected for study. 
 40 eyes of 32 patients were evaluated in terms of detailed history 
regarding onset, duration, presenting symptoms, about previous surgery 
details and treatment of eye in past and systemic conditions like diabetes, 
hypertension. 
 All patients were subjected to detailed systemic and ophthalmic 
evaluation. Relevant systemic investigations like FBS, PPBS, BP were 
done. 
 Best corrected visual acuity was recorded with Snellen’s chart. 
Anterior segment examination was done with slit lamp regarding 
presence of any signs of uveitis, to look for lens status- phakic or 
pseudophakic, position of IOL and any complications like pupillary 
capture, subluxation of IOL, vitreous in wound site. 
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 Posterior segment examination was done using slitlamp 
biomicroscopy with +90 D lens and indirect ophthalmoscope. Fundus 
photograph was taken in all cases for documentation. Fundus fluorescein 
angiography was done in all cases to look for flower petal leakage from 
perifoveal capillaries in macular region. Optical coherence tomography 
was done in all cases to look for type of macular edema, central macular 
thickness. Intraocular pressure was noted in all cases with Goldmann 
applanation tonometry. 
 All  patients  who  had  cystoid  spaces  in  macular  region  on  OCT,  
who were refractory to treatment like grid and focal laser 
photocoagulation in vascular causes and topical anti-inflammatory drugs 
and grid laser photocoagulation in pseudophakic cases were subjected to 
treatment with intravitreal triamcinolone acetonide injection.  
 A commercially available Triamcinolone  acetonide without 
preservative (CORTEYE 40mg/ml) is available. Under aseptic techniques 
using 5% povidone iodine and topical antibiotics, 4mg in 0.1ml of 
triaminolone acetonide was injected intravitreally in superotemporal 
quadrant via parsplana. After injection, intraocular pressure and central 
retinal artery perfusion was checked. Patients were instructed to 
administer topical antibiotics for 1 week. 
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FOLLOW UP 
 Patients were followed up on first postoperative day following 
intravitreal  injection.  They  were  followed up  at  the  end  of  first  week,  4  
weeks, 8weeks and 12 weeks. At each visit anterior segment examination 
by slit lamp biomicroscopy, intraocular pressure with Goldmann 
applanation tonometry, visual acuity recording with Snellen’s chart and 
fundus  examination  by  +90  D  was  done.  A  repeat  OCT  was  done  at  
8weeks and 12weeks to look for central macular thickness. 
 If the patient however presents with pain, ocular redness, decrease 
in visual acuity, they were instructed to contact ophthalmologist 
immediately. 
 The results published here are for a period of follow up extending 
upto six months. 
GUIDELINES FOR INTRAVITREAL INJECTION 
1. Povidone iodine application for ocular surface, eyelid and 
eyelashes. 
2.  Use  of  eye  speculum and  avoid  contamination  of  the  needle  with  
eyelid margin. 
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     3.  Avoid extensive massage of eyelids both pre and post injection. 
     4. Adequate use of topical anaesthetics. 
     5. Avoid prophylactic and post injection paracentesis. 
     6. Intraocular pressure to be checked following injection. 
     7. Dilated fundoscopic examination should be done following 
injection to look for central retinal artery perfusion and intraocular 
location of the drug. 
MAIN OUTCOME MEASURES 
1. Best corrected visual acuity (logMAR conversion of Snellen’s 
chart) 
2. Central macular thickness (µm) with OCT. 
3. Intraocular pressure (mm Hg) measurement with Goldmann’s 
applanation tonometry. 
STATISTICAL ANALYSIS 
 Data analysis was carried out by the Statistical Package For Social 
Science (SPSS). Paired t-test was done to analyse the central macular 
thickness before and after intervention. Pearson’s correlation coefficient 
was done to find out the correlation between macular thickness and visual 
acuity. 
 INTRAVITREAL TRIAMCINOLONE  
ACETONIDE INJECTION 
 
        
 
FIGURE: These pictures depict administration of Triamcinolone 
acetonide intravitreally through parsplana route. 
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ANALYSIS AND RESULTS 
1. AGE DISTRIBUTION 
 Total patients enrolled in our study is 32. 
Table - 1 
Age  (in years) No.of patients Percentage 
31 -40 2 6.25% 
41-50 4 12.5% 
51-60 12 37.5% 
61-70 12 37.5% 
71-80 2 6.25% 
 
 Majority  of  patients  in  this  study  were  in  the  age  group  of  51-70  
years (75%). The mean age of presentation was 58.53 ± 9.59 years. The 
oldest patient was 73 years and the youngest was 33 years.  
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2. SEX DISTRIBUTION 
Table - 2 
Sex No. of patients Percentage 
MALE 21 65.63% 
FEMALE 11 34.38% 
      
 In this study, there was a slight male preponderance, males 
accounting for 65.63% of patients. Majority of them were in 61 -70 years 
age group. 
 
CHART - 1 
AGE AND SEX DISTRIBUTION 
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3. LATERALITY 
Table - 3 
Eye No. of patients Percentage 
RIGHT 14 43.75% 
LEFT 10 31.25% 
BOTH 8 25% 
 
 In this study, incidence of cystoid macular edema was more in right 
eye (43.75%). In 8 cases (25%) there was a bilateral presentation. 
CHART 2 
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4. CAUSES OF  REFRACTORY CYSTOID MACULAR 
EDEMA  
Table -4 
Cause No. of eyes Percentage 
DIABETIC MACULAR EDEMA 24 60% 
PSEUDOPHAKIC MACULAR 
EDEMA 
11 27.5% 
RETINAL VEIN OCCLUSION 
WITH CME 
5 12.5% 
 
 In this study, Diabetic macular edema accounted for 60% , 
Pseudophakic  macular edema  for 27.5% , Retinal vein occlusion 
macular edema  for 12.5%. 
CHART - 3 
      
CAUSES OF  REFRACTORY CME
Diabetic macular edema
Pseudophakic edema
Retinal vein occlusion with 
macular edema
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5. ASSOCIATION OF DIABETES WITH CME  
Table - 5 
Stage of  diabetic retinopathy No. of eyes Percentage 
MILD NPDR 1 3.45% 
MODERATE NPDR 8 27.59% 
SEVERE NPDR 11 37.93% 
VERY SEVERE NPDR 5 17.24% 
PDR 4 13.79% 
TOTAL 29 100% 
 
 Out  of  40  CME  eyes,  29  eyes  were  diabetic.  Of  which,  severe  
NPDR (11 eyes) contributed to 37.93%, moderate NPDR(8 eyes) 
contributed  to  27.59%,  very  severe  NPDR  (5  eyes  )  contributed  to  
17.24%, PDR (4 eyes) contributed to 13.79%, mild NPDR (1 eye) 
contributed to 3.45%. About 11 eyes had no diabetic retinopathy. 
CHART - 4 
 
0
2
4
6
8
10
12
MILD NPDR MODERATE NPDR SEVERE NPDR VERY SEVERE 
NPDR
PDR
DIABETIC RETINOPATHY STAGING
58 
 
6.  DATA ANALYSIS IN DIABETIC MACULAR EDEMA 
Table 6 
PRE TREATMENT MACULAR THICKNESS 
Macular Thickness No.of eyes Percentage 
300 – 400 µ 3 12.5% 
400 – 600 µ 8 33.4% 
600 – 800 µ 6 25% 
800 – 1000 µ 5 20.8% 
 >1000 µ 2 8.3% 
 
 The mean pre treatment macular thickness  is 670.38 ± 216.27µm, 
(S.E-44.14). 
Table 7 
POST TREATMENT MACULAR THICKNESS 
Macular Thickness 
8 Weeks 12 Weeks 
No. of eyes % No. of eyes % 
< 200 µ 0 0% 6 25% 
200 – 400 µ 13 54.17% 18 75% 
400 – 600 µ 11 45.83% 0 0% 
600 – 800 µ 0 0% 0 0% 
8000 – 1000 µ 0 0% 0 0% 
>1000 µ 0 0% 0 0% 
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CHART - 5 
Comparison of Pre and Post Treatment Macular Thickness in DME 
 
      The mean macular thickness at 8 weeks and 12 weeks post 
intervention were 385.46 ± 90.31 µm (S.E – 19.02 ) and 247.25 ± 58.41 
µm (S.E – 11.92) respectively.  
 Paired  t  test  showed  the  two  tailed  ‘p’  value  is  <0.0001 which 
means there is a significant difference in central macular thickness before 
and after IVTA at 8 weeks as well as 12 weeks. 
 The mean  reduction in macular thickness at 8 weeks and 12 weeks 
post intervention were 285.25 ± 158.07 µm (S.E – 32.27) and 423.13 ± 
196.55 µm (S.E – 40.12) respectively.   
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VISUAL ACUITY 
Table - 8 
Visual acuity 
Pre Treatment 
Post Treatment 
at 12 Weeks 
No.of eyes % No.of eyes % 
1/60 – 2/60 1 4.17% 1 4.17% 
3/60 – 4/60 3 12.5% 1 4.17% 
5/60 - 6/60 12 50% 2 8.33% 
6/36 – 6/24 8 33.33% 5 20.83% 
6/18 – 6/12 0% 0% 11 45.83% 
6/9 – 6/6 0 0% 4 16.67% 
 
 
 After  logMAR conversion , mean visual acuity was found to be 
0.98 (6/60) ± 0.21 before  IVTA and 0.52 (6/18) ± 0.34 after IVTA. In 
paired t-test, ‘p’ value was <0.0001 which signifies the improvement in 
visual acuity. 
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CHART - 6 
Comparison between Pre and Post Treatment Visual acuity in DME 
 
  
 All patients in my study presented with visual acuity between 2/60 
- 6/24. Majority of them had 6/36 – 6/24 (58.3%). After treatment with 
IVTA, at 8 weeks, 54.17% of patients gained vision upto 6/18 – 6/12. At 
12 weeks, 4 out of 24 cases (16.67%) gained 6/9 vision and 11 out of 24 
cases (45.83%) gained vision upto 6/12. Only 4 cases (16.67%) did not 
regain significant visual improvement and were less than 6/60. 
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CORRELATION BETWEEN MACULAR THICKNESS AND 
VISUAL ACUITY 
 By Pearson's correlation coefficient, ‘r’ value was 0.61 suggesting 
a MODERATELY POSITIVE correlation between macular thickness 
and visual acuity before treatment whereas ‘r’ value post treatment(12 
weeks) was -0.01 suggesting a weakly negative correlation between the 
same. 
CHART - 7 
 
 
      This chart explains the correlation between macular thickness and 
visual acuity post IVTA in Refractory DME. 
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7. DATA ANALYSIS IN PSEUDOPHAKIC EDEMA 
PRE TREATMENT MACULAR THICKNESS 
Table 9  
Macular Thickness No.of Eyes Percentage 
300 – 400 µ 0 0% 
400 – 600 µ 2 18.1% 
600 – 800 µ 4 36.4% 
800 – 1000 µ 5 45.5% 
 >1000 µ 0 0% 
 
 The mean macular thickness before treatment is  
763.45 ± 148.57µm (SE-44.71). 
POST TREATMENT MACULAR THICKNESS 
Table 10 
Macular Thickness At 8 Weeks At 12 Weeks 
No.of eyes % No.of eyes % 
< 200 µ 0 0% 0 0% 
200 – 400 µ 4 36.36% 10 90.09% 
400 – 600 µ 5 45.45% 0 0% 
600 – 800 µ 2 18.18% 1 9.09% 
8000 – 1000 µ 0 0% 0 0% 
>1000 µ 0 0% 0 0% 
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Comparison of Pre and Post Treatment Macular Thickness in 
Pseudophakic CME 
Chart - 8 
 
 The mean macular thickness after treatment at 8 weeks is 486.18 ± 
123.53µm (SE-38.75) and at 12 weeks is 312.55 ± 119.41µm(SE-36.00).  
 Paired  t  test  showed  the  two  tailed  ‘p’  value  is  <0.0001 which 
means there is a significant difference in central macular thickness before 
and after IVTA at 8 weeks as well as 12 weeks. 
 The mean  reduction in macular thickness at 8 weeks and 12 weeks 
post intervention were 276.91 ± 89.53 µm (S.E – 26.99) and 450.55 ± 
126.40 µm (S.E – 38.11) respectively. 
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POST TREATMENT VISUAL ACUITY 
Table 11 
Visual Acuity 
Pre Treatment Post Treatment -  12 Weeks 
No. of eyes % No. of eyes % 
1/60 – 2/60 0 0% 0 0% 
3/60 – 4/60 1 9% 0 0% 
5/60 - 6/60 5 45.50% 1 9.09% 
6/36 – 6/24 5 45.50% 4 36.36% 
6/18 – 6/12 0 0% 5 45.46% 
6/9 – 6/6 0 0% 1 9.09% 
 
           After  logMAR conversion , mean visual acuity was found to be 
0.87 (6/36) ± 0.21 before  IVTA and 0.53(6/18) ± 0.26 after IVTA. In 
paired t-test, ‘p’ value = 0.0003 which signifies the improvement in 
visual acuity. 
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Comparison of Pre and Post Treatment Visual acuity  
Improvement in Pseudophakic CME 
Chart - 9 
 
 All patients in my study presented with visual acuity between 2/60 
- 6/24. Majority of them had 5/60 – 6/24 (91%). After treatment with 
IVTA, at 8 weeks, 54.55% of patients gained vision upto 6/18 – 6/12. At 
12 weeks, 5 out of 11 cases (45.46%) gained 6/12 vision. 1 case regained 
vision upto 6/9.  1 case (9.09%) did not regain significant visual 
improvement and was less than 6/60 due to hole formation. 
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CORRELATION BETWEEN MACULAR THICKNESS AND 
VISUAL ACUITY 
 By Pearson's correlation coefficient, ‘r’ value was 0.46 suggesting 
a WEAK POSITIVE correlation between macular thickness and visual 
acuity before treatment whereas ‘r’ value post treatment(12 weeks) was 
0.72 suggesting a STRONG POSITIVE correlation between the same. 
CHART - 10 
 
 This chart explains the correlation between macular thickness and 
visual acuity post intervention in Pseudophakic CME. 
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8.  DATA ANALYSIS IN RETINAL VEIN OCCLUSION 
MACULAR EDEMA 
PRE TREATMENT MACULAR THICKNESS 
Table 12 
Macular Thickness No.of Eyes Percentage 
300 – 400 µ 2 40% 
400 – 600 µ 1 20% 
600 – 800 µ 2 40% 
800 – 1000 µ 0 0% 
 >1000 µ 0 0% 
 
 The pre treatment mean macular thickness is 541.2 ± 183.97µm 
(SE -82.28). 
POST TREATMENT MACULAR THICKNESS 
Table 13 
Macular Thickness At 8 Weeks At 12 Weeks 
< 200 µ 0 2 
200 – 400 µ 3 3 
400 – 600 µ 2 0 
600 – 800 µ 0 0 
8000 – 1000 µ 0 0 
>1000 µ 0 0 
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Comparison of Pre and Post Treatment Macular Thickness in 
Retinal Vein Occlusion Macular Edema 
CHART - 11 
 
 The mean macular thickness post treatment at 8 weeks and  
12 weeks were 381.6 ± 150.30µm (SE– 67.22 ) and 222.8 ± 42.83µm 
(SE-19.16).  
 Paired t test showed that  there is a significant difference in central 
macular  thickness  before  and  after  IVTA  at  8  weeks  &  12  weeks,  ‘  p’  
values being  0.0179, 0.009 respectively. 
 The mean  reduction in macular thickness at 8 weeks and 12 weeks 
post intervention were 276.91 ± 89.53 µm (S.E – 26.99) and 450.55 ± 
126.40 µm (S.E – 38.11) respectively. 
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VISUAL ACUITY 
Table 14 
Visual Acuity Pre Treatment Post Treatment At  
12 Weeks 
No.of eyes % No.of eyes % 
1/60 – 2/60 0 0% 0 0% 
3/60 – 4/60 2 40% 0 0% 
5/60 - 6/60 1 20% 2 40% 
6/36 – 6/24 2 40% 2 40% 
6/18 – 6/12 0 0% 1 20% 
6/9 – 6/6 0 0% 0 0% 
 
 After  logMAR conversion, mean visual acuity was found to be 
0.97 (6/60) ±  0.28 before  IVTA and 0.70(6/36) ± 0.3 after IVTA.  
In  paired  t-test,  ‘p’  value   =  0.0084 which signifies the improvement in 
visual acuity. 
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Comparison of Pre and Post Treatment Visual acuity Improvement 
in Retinal Vein Occlusion Macular Edema 
 
CHART - 12 
     
 
      
 All patients in my study presented with visual acuity between 3/60 
- 6/24. After treatment with IVTA, at 8 weeks, 1 patient gained vision 
upto 6/18 – 6/12. At 12 weeks, the same patient retained his 6/12 vision. 
Due to longstanding macular edema, average of 1 snellen line visual 
improvement only was noted.  
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CORRELATION BETWEEN MACULAR THICKNESS AND 
VISUAL ACUITY 
     By  Pearson's  correlation  coefficient,  ‘r’  value  was  0.62  suggesting  a  
MODERATE POSITIVE correlation between macular thickness and 
visual acuity before treatment whereas ‘r’ value post treatment(12 weeks) 
was 0.15 suggesting a WEAK POSITIVE correlation between the same. 
CHART -13 
 
 This chart explains the correlation between macular thickness and 
visual acuity post injection in retinal vein occlusion CME. 
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9. COMPARISON OF REDUCTION IN CENTRAL MACULAR 
THICKNESS AMONG THREE GROUP OF PATIENTS 
Table - 15 
Group 
Frequency 
(No.of Eyes) 
Mean CMT at  
8 Weeks 
Mean CMT at  
12 Weeks 
DME 24 285.25 ± 158.07 423.13 ± 196.55 
Retinal vein 
occlusion CME 
5 159.60 ± 64.58 318.40 ± 148.52 
Pseudophakic 
CME 
11 276.91 ± 89.53 450.55 ± 126.398 
          
 Maximum mean reduction in IOP was seen in Diabetic macular 
edema at  8 weeks.  At the end of  12 weeks,   Pseudophakic  CME had a 
significant reduction in IOP. 
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10. INTRAOCULAR PRESSURE 
Table - 16 
IOP(mmHg) 
No.of Eyes 
Pretreatment 1 week 12 weeks 
<12 2 3 2 
12 -16 23 20 25 
16 - 20 15 8 12 
>20 0 9 1 
 
 The mean pre treatment IOP was  16.05 ± 2.14 mm Hg. The mean 
post treatment IOP at 1 week and 12 weeks respectively were 17.4 ± 3.93 
mm Hg and 16.05 ± 2.29 mm Hg 
 Out of 40 eyes, 9 eyes showed a rise in IOP accounting for 22.5%.  
Of which 1 patient was refractory to treatment with topical antiglaucoma 
drugs and needed trabeculectomy and all others were manageable with 
topical anti glaucoma drugs. 
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DISCUSSION 
x  AGE DISTRIBUTION 
     In this study of 32 patients, majority of the patients  (75%) belong  
to 5th and 6th decades. This may be due to the fact that most of cataract 
surgeries take place in this age group and prevalence of systemic diseases 
like DM and HT is more common in this age group. We had 6 cases 
below 50 years accounting for 18.75% of patients. Previous  studies 
showed similar involvement. (Daniel M.Taylor et al.(21) Survey 
ophthalmology) 
x  SEX DISTRIBUTION 
 The study revealed a slight Male preponderance with a male to 
female ratio of 1.9:1.  
x  LATERALITY 
 In this study, RE (43.75%) was more commonly involved than 
LE(31.25%), bilateral(25%) presentation being uncommon relatively. 
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x  ETIOLOGY 
 DIABETES shares the highest proportion of 60% followed by 
PSEUDOPHAKIA (27.5%), last being VEIN OCCLUSION(12.5%). 
x  CME IN RELATION TO SURGICAL COMPLICATONS 
 About 9 cases had posterior capsular rent and 2 cases had iritis in 
this study. A posterior capsular rent leads to loss of barrier effect, thus 
predisposing to develop CME. The increased association of CME with 
post op iritis has been well documented by Marvin L.Sears (Surv. 
Ophthalmol 28(suppl) :525-534,1984)(22) who states occurrence of CME 
after ocular trauma (surgery) is related to synthesis and release of 
endogenous mediators like prostaglandins. 
 About 33.3% (6 cases) developed CME despite an uncomplicated 
surgery and uneventful post operative period. This may be because of 
ocular trauma caused by surgery leading to synthesis of inflammatory 
mediators that lead diffuse posteriorly and also because of nonfunctioning 
of Bito’s(23) pump in ciliary epithelium for 3 weeks post surgery. Some 
patients have an inherent predisposition for development of CME like 
DM, HT.  
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x  CME IN DIABETES MELLITUS 
 Out of 40 eyes studied, 29 eyes suffered diabetic retinopathy of 
which 11 patients belonged to severe NPDR stage followed in order by 
moderate NPDR(8), very severe NPDR(5), PDR(4), mild NPDR(1). 
x  ASSOCIATION OF PVD 
 Out  of  40  eyes,  11  eyes  (27.5%)  that  had  incomplete  PVD and  7  
eyes(22.5%) with complete PVD on OCT. A total of 18 eyes accounting 
for 45% had either complete or incomplete PVD. Remaining 22 
eyes(55%) did not have PVD. 
 Following  cataract extraction, loss of hyaluronic acid from 
vitreous gel occurs, which accelerates vitreous degeneration. Combined 
with forward movement of vitreous body as a result of removal of 
crystalline lens, the loss of hyaluronic acid precipitates vitreous 
detachment. Firm attachments of vitreous cortex to retina are usually 
present at macula and optic disc. These normal vitreoretinal adhesions 
become focal sites of vitreoretinal traction when a PVD occurs 
predisposing to CME. A study by Schepens CL et al.(Ophthalmology 96 
(10) : 1511-6,1989 Oct.)(24) gives  a  42.1% incidence  of  PVD in  patients  
with postoperative CME. 
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x  IVTA AND MACULAR THICKNESS  
 In a country like India with high number of diabetics, visual 
morbidity due to DME is very high. Intravitreal triamcinolone acetonide 
is a promising therapeutic method for diabetic macular edema. As of 
current practice, according to ETDRS, laser photocoagulation is 
advocated for DME. However refractory edema can be treated with 
intravitreal Triamcinolone. Studies focused on macular edema that failed 
to respond to conventional laser photocoagulation (Martidis(25) et al., 
Karacorlu(26) et al., Audren(27) et al., Gilles(28) et al., ophthalmology 2006)  
stated that IVTA is effective in improving vision, reducing macular 
thickness and inducing reabsorption of hard exudates in diffuse diabetic 
macular edema.  
 In cases of macular edema due to venous occlusions, the recently 
concluded SCORE(31) study  clearly  mentions  the  benefit  of  IVTA  as  
compared to standard therapy in CRVO. In BRVO, Triamcinolone and 
Grid laser shows a comparable response, however triamcinolone can be 
used for macular edema not responding to laser therapy. 
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 In case of pseudophakic CME, Boscia(29) et al., states that reduction 
in mean macular thickness from 517.29 ± 146.98 µm to 263.71 ± 83.13 
µm at 3 months of followup. 
 There was a significant reduction (statistically proven by paired  
t-test) in central macular thickness in all three groups both at 8 weeks and 
12 weeks follow up period. Maximum reduction in macular thickness at 8 
weeks was observed in diabetic group(285.25±158.07) whereas after 12 
weeks follow up period, the reduction was highest in the pseudophakic 
group(450.55±126.398).  
x  VISUAL ACUITY  
 In DME, visual acuity showed a significant improvement from 
6/60 before intervention  to 6/24 after intervention which means  an 
average two Snellen line improvement. 
 In pseudophakic CME, patients showed an average 2 Snellen line 
visual improvement which is significant ( 6/36 to 6/18). 
 In venous occlusion, visual acuity improvement was significant as 
in other groups, which was an average one snellen line improvement from 
6/60 to 6/36. 
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x  INTRAOCULAR PRESSURE 
 9 eyes of total 40 eyes (22.5 %) showed an increase in intraocular 
pressure on immediate post operative day and 1 week follow up. But 6 
out of 7 cases were responded well to topical antiglaucoma drugs. 
However in my study, 1 case  was refractory to topical medications and 
required antiglaucoma surgery to control IOP. Recent studies (Rhee(30)  
et al., Boscia(29) et al.) found a 35% and 57% increase in IOP following 
IVTA in follow up weeks controlled by topical medications.  
x  CATARACT  
 A recent study by Gillies(28) et al., has demonstrated that steroid 
related cataracts are more likely to form in patients who are steroid 
responders. In this study , as the follow up period  was only  6months, 
and lens changes were not excluded in the beginning, progression of lens 
changes could not be assessed. 
x  RECURRENCE OF MACULAR EDEMA 
 Massin(27) et al., looked at patients unresponsive to laser 
photocoagulation and found a significant difference between CMT of 
eyes injected with 4mg IVTA and control eyes but effect was no longer 
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significant at 24 weeks because of recurrence of macular edema. This 
transient reduction in CMT correlated also to visual acuity. 
 In this study, about 50% eyes needed a repeat injection of IVTA 
who had a follow up of over 6 months due to weaning effect of the drug. 
COMPLICATIONS 
 Refractory cases who did not show visual acuity improvement 
despite reduction in macular thickness had complications like ERM, 
Macular hole was seen in 7 eyes of total 40 eyes accounting for 17.5%. 
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SUMMARY 
x This is a one year prospective , non randomized clinical study to 
evaluate the efficacy and safety of Intravitreal triamcinolone 
acetonide in treatment of refractory cystoid macular edema. 
x The main aim was to evaluate the improvement in visual acuity and 
decrease in macular thickness in refractory cases like DME, 
pseudophakic CME, retinal venous occlusion CME. 
x The occurence of adverse effects like increase in intraocular 
pressure were noted. 
x In this study, 40 eyes of 32 patients were analysed and followed up 
for a period of 6 months. 
x The mean age of presentation is 58.33 ± 9.5 years with a slight 
male preponderance with male : female ratio of  1.9 :1. 
x Diabetes was found to be the leading causse (60%) followed in 
order by pseudophakia (27.5%) and venous occlusion (12.5%) 
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x Among various known complications, significant association  of 
CME was found with posterior capsular rent and post operative 
iritis mediated by prostaglandins. About 33.3% of CME developed 
in uneventful intra and post operative period. 
x Out of 40 eyes studied, 29 eyes suffered diabetic retinopathy, of 
which severe NPDR outnumbered other stages. 
x This study supports previous reviews of literature stating a 50% 
association of PVD in CME eyes. 
x  MACULAR THICKNESS 
 Based  on  analysis  of  data  available,  there  has  been  a  substantial  
reduction in central macular thickness after IVTA administration during 
8th and 12th week follow up in all three groups. 
x  VISUAL ACUITY 
 Visual acuity showed on an average of 2 Snellen line improvement 
in diabetic and pseudophakic CME and 1 Snellen line improvement, 
albeit, significant  in venous occlusion CME. 
 Though visual acuity has improved in all 3 groups, it is not in 
correspondence with reduction in central macular thickness which can be 
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explained by  photoreceptors derangement secondary to chronic macular 
edema. 
x  INTRA OCULAR PRESSURE 
 Intra ocular pressure risc noted in 22.5% eyes which responded 
well to topical antiglaucoma drugs in most cases. 1 case was refractory to 
medical therapy needing surgical intervention. 
x  LIMITATIONS OF STUDY  
 Lens changes (status) becomes a major confounding factor while 
analysing the complications of intravitreal Triamcinolone. This has not 
been addressed in the study. 
 While considering the weak correlation between reduction in 
macular thickness and visual acuity improvement, the possibilityof 
macular ischemia has to be ruled out which the study did not take into 
account. 
 Larger study group  necessary to quantify the actual magnitude of 
benefit of this treatment modality with comparison to other therapies. 
 Longer follow up is necessary to document the post injection 
recurrences and progression of cataract. 
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CONCLUSION 
 Cystoid macular edema presented mostly in the 5th and  6th decade 
with slight male preponderance. This study describes diabetic retinopathy 
as the leading etiology with highest association with severe NPDR stage. 
 The fall in Mean macular thickness after IVTA was statistically 
significant in all three groups analysed. Etiology wise diabetic 
(423.13±196.55µm) and pseudophakic (450.55±126.398 µm) patients 
seem to be benefitted more than patients suffering from vein occlusion 
with greater reduction in mean macular thickness. 
 Among the three groups visual acuity improvement was on an 
average 2 Snellen line in diabetes and pseudophakic groups whereas in 
vein occlusion group was only 1 Snellen line improvement. 
 The correlation between Mean macular thickness and visual acuity 
pre treatment was moderate to strong positive in all 3 groups whereas 
there was a weak positive or neagative correlation post treatment due to 
underlying photoreceptor damage. 
 Intravitreal Triamcinolone acetonide is a promising therapy in 
refractory cystoid macular edema with established safety and 
effectiveness. Further study with a longer follow-up period and larger 
series is warranted to assess the treatment's long term efficacy and safety 
and the need for retreatment.  
COMPARISON BETWEEN PRE AND POST TREATMENT 
MACULAR OCT 
CASE REPORT -1 
 
FIGURE 1: Pre injection: OCT shows cystoid spaces intraretinally with 
serous macular detachment. Central macular thickness is 1111µm. 
 
 
FIGURE 2: 12 Weeks Post injection: Repeat OCT shows reduction in 
cystoid spaces with macular thickness 183µm. 
 
CASE - 2 
 
FIGURE 1: Pre injection cystoid change noted  in the retina 
 
 
FIGURE 2: Post injection 12 weeks, cystoid edema has completely 
resolved with reduction in macular thickness. However  visual acuity 
showed a minimal improvement by 1 line. The patient had a venous 
occlusion for about 1 year. 
  
CASE – 3 
      
FIGURE 1: Pretreatment 
 
      
FIGURE 2: Post treatment 12 weeks showing a reduction in CMT 
  
CASE – 4 
 
FIGURE 1: Pre injection: Multiple cystoid  spaces with macular 
detachment 
 
FIGURE 2: Post treatment showing 50% reduction in macular thickness. 
  
CASE – 5 
 
FIGURE  1: Pre treatment 
 
 
FIGURE 2: Post treatment reduction in macular edema 
  
  
 
PART - III 
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PROFORMA FOR CLINICAL STUDY ON CYSTOID  
MACULAR EDEMA 
1. NAME :  
2. AGE/SEX : 
3. OP/IP No. : 
4. OCCUPATION : 
5. ADDRESS : 
6. PHONE No. : 
7. PRESENTING COMPLAINTS-  
A) DEFECTIVE VISION- RE/LE 
                                   MILD/MOD/SEVERE/GRADUAL/SUDDEN 
                                   DURATION 
 
B) OTHER COMPLAINTS- PAIN/REDNESS/ WATERING/ 
PHOTOPHOBIA/METAMORPHOSIA/POSITIVE SCOTOMA 
 
C) DETAILS OF ANY SURGERY- TYPE OF SURGERY                                                  
ANY COMPLICATION DURING SURGERY- PC RENT,                                               
VITREOUS DISTURBANCE,  
                                                 DATE OF SURGERY  
                                                 POST OPERATIVE COMPLICATION- SK, 
IRITIS, IRIS PROLAPSE, IOL POSITION, 
PUPILLARY CAPTURE, PCO 
                                               TYPE AND DURATION OF TOPICAL 
MEDICATIONS 
                                                 
D) HISTORY OF SYSTEMIC CONDITIONS- DM, HT, IHD, RENAL 
DISEASE 
E)  HISTORY OF DM- IDDM/NIDDM 
                               DURATION 
                                STAGE OF DIABETIC RETINOPATHY 
                                TREATMENT DETAILS(OHA/INSULIN) 
                                OCULAR TREATMENT(PRP/GRID)-  
      No. Of sittings 
                                OTHER SYSTEM INVOLVEMENT-  
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     NEPHROPATHY/NEUROPATHY 
                                UNDER CONTROL/NOT 
F) HISTORY OF HYERTENSION- DURATION                        
               UNDER CONTROL WITH DRUGS 
 ANY ASSOCIATED IHD, HYPERLIPIDEMIA, CVA 
       
8. EXAMINATION- 
 1] UCVA/BCVA/VA WITH PH                   
     RE                            LE 
 2] ANTERIOR SEGMENT- SLE 
 3] IDO AND 90D- 
 4] IOP 
 5] COLOUR VISION 
 6] FIELDS 
 
9.  INVESTIGATION-        1] FBS/PPBS 
                                 2]URINE ALB/SUGAR 
                                 3]SERUM CHOLESTEROL(IN RVO) 
                                 5]BP 
10.  FUNDUS PHOTO 
11.   FFA-  
12.  OCT- MACULAR THICKNESS 
       DIAGNOSIS - 
13.  IVTA-Y/N 
 DATE 
 NO/OF SITTINGS 
 PRE V/A 
 FOLLOW UP-  NEXT  DAY- VA /IOP/FUNDUS/  
 ANT SEGMENT 
            1 WEEK 
                    4WEEKS 
                    8WEEKS     
                   12 WEEKS 
                                  RPT OCT- CMT 
                                  RPT INJECTION NEEDED-Y/N 
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INDEX TO MASTER CHART 
SEX    - M – Male 
    F – Female 
DM     - Diabetes mellitus 
    Y – Yes 
    N – No 
    1 – No Diabetic retinopathy 
    2 – Mild NPDR 
    3 – Moderate NPDR 
    4 – Severe NPDR 
    5 – Very severe NPDR 
    6 – PDR 
HT    - Hypertension 
EYE AFFECTED - RE – Right eye 
    LE – Left eye 
DIAGNOSIS -      1 – Pseudophakic CME 
    2 – Retinal vein occlusion with CME 
    3 – Diabetic CME 
VA     –  Visual acuity 
PH     – Pin hole 
NIP     –  Not improving with pinhole 
PVD    – Posterior vitreous detachment 
    1 – No PVD 
         2 – Incomplete PVD 
    3 – Complete PVD 
IOP     – Intraocular pressure (in mmHg) 
OCT    – Optical coherence tomography 
CMT    – Central macular thickness (in µm) 
S.No. NAME AGE SEX DM HT PVD
EYE
AFFECTED
DIAGNOSIS
VA ON 
PRESENTATION
VA 
4WEEKS
VA 
8WEEKS
VA 
12 WEEKS
PRE 
CMT 
CMT 
8WEEKS
CMT 
12WEEKS
INITIAL
IOP
IOP
1WEEK
IOP 
12 WEEKS
COMPLI
1 KANAGASABAI 56 M N N 3 LE 1 4/60 NIP 4/60PH6/60 6/60PH6/36 6/24NIP 918 636 358 14 14 14 -
2 MOHAMMED SAQUEB 52 M Y3 Y 1 LE 3 6/60PH6/36 6/60PH6/36 6/36PH6/24 6/36PH6/24 754 476 325 16 16 16 ERM
3 KUPPAMMAL 52 F Y3 N 1 LE 3 6/36NIP 6/36PH6/24 6/24PH6/18 6/12PH6/9 370 285 190 16 16 16 -
4 MURUGAVEL 54 M N Y 3 RE 2 6/36PH6/24 6/24PH6/18 6/18PH6/12 6/18PH6/12 354 276 185 18 18 16 -
5 RAJA 47 M Y6 N 1 RE 3 6/60PH6/36 6/60PH6/36 6/36PH6/24 6/24PH6/18 836 498 298 16 16 16 -
6 MARIMUTHU 66 M Y1 N 1 RE 1 6/36PH6/24 6/36PH6/24 6/24PH6/12 6/12NIP 550 350 229 12 12 14 ERM
7 ASOKAN 49 M Y3 N 1 LE 3 6/24NIP 6/24PH6/18 6/18PH6/12 6/12PH6/9 350 212 194 14 22 14 -
8 DEVARAJULU 68 M Y4 Y 2 LE 3 4/60 NIP 2/60 NIP 2/60 NIP 2/60 NIP 471 312 205 18 24 18 -
9 KANNAYIRAM 73 M N N 2 RE 1 4/60PH6/60 5/60PH6/60 6/60PH6/36 6/36 NIP 974 534 312 18 18 18 -
10 SELVANAYAGAM 68 M Y4 N 1 RE 3 6/60 NIP 6/36PH6/24 6/18PH6/12 6/12NIP 589 312 185 12 12 12 -
11 ANNAPOORANI 58 F N N 1 RE 1 6/60 NIP 6/60PH6/36 6/24PH6/18 6/18PH6/12 563 338 224 18 18 18 -
12 DAKSHINAMOORTHY 60 M Y6 N 1 LE 3 3/60PH6/60 5/60PH6/60 6/36PH6/24 6/24PH6/18 1153 445 290 18 18 18 -
13 SAROJA 58 F Y4 Y 1 RE 3 6/60NIP 6/60PH6/36 6/36PH6/24 6/18NIP 476 320 198 14 14 14 -
14 JAGANATHAN 65 M Y3 N 1 RE 1 6/60PH6/24 6/36PH6/24 6/18PH6/12 6/12PH6/9 860 454 254 18 18 18 -
15 ELUMALAI 42 M Y5 N 3 RE 3 6/60PH6/36 6/36PH6/18 6/24PH6/12 6/24PH6/12 897 512 240 14 14 14 -
16 RAJENDRAN 62 M N Y 3 RE 2 4/60 NIP 4/60NIP 4/60PH6/60 6/60PH6/36 745 510 240 20 20 20 ERM
17 GANGADHARAN 59 M Y4 N 2 RE 3 5/60NIP 6/60NIP 6/60NIP 6/60NIP 618 376 220 18 22 24 ERM
18 SUNDARAMMAL 66 F Y4 N 1 RE 3 6/60NIP 6/60PH6/36 6/24PH6/18 6/18NIP 600 474 320 16 16 16 -
19 KASTHURI 40 F N N 2 LE 1 6/24NIP 6/24NIP 6/24PH6/18 6/18PH6/12 754 554 336 18 16 16
LAMELLAR 
HOLE
20 BABU 33 M Y4 Y 2 LE 3 6/60PH6/36 6/36PH6/24 6/24NIP 6/24NIP 836 536 398 14 14 14 ERM
21 KANNIYAPPAN 72 M Y3 N 1 LE 1 5/60PH6/36 6/60PH6/24 6/24PH6/18 6/18 NIP 608 373 229 14 14 14 -
22 VIJAYARAGHAVAN 7 M Y6 N 3 RE 3 6/36PH6/18P 6/36PH6/24 6/24PH6/18 6/12PH6/9 633 334 279 18 18 18 -
23 BABYAMMAL 61 F N Y 2 LE 2 2/60PH3/60 4/60PH6/60 4/60PH6/60 6/60PH6/36 494 280 197 16 18 16 ERM
24 ELUMALAI 42 M Y5 N 1 LE 3 6/36PH6/24 6/24PH6/18 6/18PH6/12 6/18PH6/12 750 390 220 16 16 16 -
25 REVATHI 65 F Y5 N 1 LE 3 6/36NIP 6/24PH6/18 6/18PH6/12 6/12NIP 598 378 224 14 14 14 -
26 ASOKAN 70 M N Y 3 RE 1 4/60PH6/60 6/60PH6/36 6/36PH6/24 6/24NIP 794 458 302 18 28 18 -
27 AHMED 62 M Y4 N 1 LE 3 2/60NIP 2/60 NIP 4/60NIP 4/60 NIP 758 498 216 18 22 18 -
28 GOVINDARAJ 50 M Y3 Y 1 RE 2 6/60PH6/36 6/36PH6/24 6/24PH6/18 6/18PH6/12 389 264 202 16 16 16 -
29 MEENA 60 F Y4 N 1 RE 3 6/60PH6/24 6/60PH6/24 6/24PH6/12 6/12PH6/9 393 210 185 16 16 16 -
30 REVATHI 65 F Y5 N 3 RE 3 6/36PH6/24 6/24PH6/18 6/18PH6/12 6/12 NIP 538 354 210 14 14 14 -
31 KOTHANDAN 63 M N Y 2 LE 1 2/60PH5/60 3/60PH5/60 5/60 NIP 5/60NIP 903 754 645 14 14 14 -
32 MALARVIZHI 59 F Y5 Y 3 LE 3 3/60PH6/60 5/60PH6/60 6/36NIP 6/36NIP 842 365 195 20 22 18 -
33 ASOKAN 70 M N Y 1 LE 1 6/60PH6/36 6/36PH6/24 6/24PH6/18 6/18NIP 663 393 250 18 24 18 -
34 DAKSHINAMOORTHY 60 M Y4 N 1 RE 3 6/60PH6/36 6/36PH6/24 6/24PH6/18 6/18NIP 1049 460 312 16 18 16 -
35 MALLIGA 56 F Y3 N 3 RE 3 6/36NIP 6/36PH6/24 6/24PH6/18 6/18PH6/12 462 312 208 16 16 16 -
36 SELVARANI 52 F Y1 Y 1 LE 2 5/60PH6/60 6/60PH6/36 6/36PH6/24 6/24NIP 724 578 290 14 14 14 -
37 BABU 33 M Y4 Y 2 RE 3 6/36PH6/24 6/36PH6/24 6/24NIP 6/24NIP 479 458 312 14 14 14 ERM
38 KOTHANDAN 63 M N Y 2 RE 1 5/60PH6/60 6/60PH6/36 6/36 NIP 6/36 NIP 807 504 299 14 12 12 -
39 MALARVIZHI 59 F Y6 Y 1 RE 3 3/60PH6/60 5/60PH6/60 6/60NIP 6/60NIP 947 422 212 20 26 18 -
40 SUNDARAMMAL 66 F Y4 N 1 LE 3 6/60NIP 6/36PH6/24 6/24PH6/18 6/12NIP 690 412 298 16 16 16 -
MASTER CHART
